Efficacy and Tolerability of Steroid-Free, Over-the-Counter Treatment Formulations in Infants and Children With Atopic Dermatitis

Abstract

BackgroundTwo steroid-free, over-the-counter skin protectant products have been developed for the care and treatment of atopic dermatitis (AD)—Eucerin Eczema Relief Body Crème (Body Cream) for daily skin moisturization and Eucerin Eczema Relief Instant Therapy cream (Instant Therapy) for treatment of AD flare-ups. We tested the efficacy and tolerability of these formulations in infants and children with AD.MethodsStudy 1: Body Cream was applied twice daily to the lower legs of 64 children with a history of AD (aged 3 months to 12 years) for 14 days. Study 2: Instant Therapy was applied to active lesions and surrounding skin of 29 children (aged 3 months to 12 years) with active atopic lesions. Assessments were performed at baseline and Days 7 and 14. Symptoms were assessed using the Atopic Dermatitis Severity Index in Study 2.ResultsBody Cream significantly improved skin hydration and reduced itching, burning/stinging, erythema, and tactile roughness. Instant Therapy significantly improved skin hydration and AD symptoms, notably pruritus, erythema, and lichenification. Both products were safe and well tolerated.DiscussionBody Cream and Instant Therapy were effective and well tolerated in the treatment of AD in children. These products provide steroid-free, nonprescription therapy for the maintenance and treatment of acute eczema and were proven effective and safe in infants as young as 3 months.

Tolerability and efficacy of a medical device repairing emollient cream in adults with chronic hand dermatitis

“…The most frequent AEs reported by subjects were mild, transient burning or warm sensations, stinging, and erythema during the first days of application. Similar mild discomfort has been observed for emollient treatments for atopic dermatitis, which is not surprising because defects in the cutaneous barrier can make the skin sensitive …”

Understanding the Burden of Atopic Dermatitis in Africa and the Middle East

“…Taking into consideration the unmet needs of AD patients in Africa and the Middle East, we outlined treatment recommendations for management of AD in these patient populations in Table 3 based on literature [ 16 , 20 , 70 – 93 ] and our clinical experience. The goal of treatment should be threefold: to break the itch–rash cycle by controlling pruritus, to suppress inflammation, and to restore skin barrier function.…”

A new topical panthenol-containing emollient: skin-moisturizing effect following single and prolonged usage in healthy adults, and tolerability in healthy infants

“…However, considering other pediatric studies, it was expected that local tolerability of NTP-CE can be assessed with the selected sample size (24)(25)(26). The primary study objective was to assess the cutaneous tolerability of NTP-CE when applied twice-daily on face and body for 4 weeks.…”